Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Files

688443.pdf (190.13 KB)

Document type

Article

Version

Published version

Publication date

2019-05-01

Publication license

cc by-nc (c) Podlipnik, et. al., 2019
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/172407

Early outcome of a 31-gene expression profile test in 86 AJCC stage IB-II melanoma patients

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

https://doi.org/10.1111/jdv.15454

Abstract

Background: The clinical and pathological features of primary melanoma are not sufficiently sensitive to accurately predict which patients are at a greater risk of relapse. Recently, a 31-gene expression profile (DecisionDx-Melanoma) test has shown promising results. Objectives: To evaluate the early prognostic performance of a genetic signature in a multicentre prospectively evaluated cohort. Methods: Inclusion of patients with AJCC stages IB and II conducted between April 2015 and December 2016. All patients were followed up prospectively to assess their risk of relapse. Prognostic performance of this test was evaluated individually and later combined with the AJCC staging system. Prognostic accuracy of disease-free survival was determined using Kaplan-Meier curves and Cox regression analysis. Results of the gene expression profile test were designated as Class 1 (low risk) and Class 2 (high risk). Results: Median follow-up time was 26 months (IQR 22-30). The gene expression profile test was performed with 86 patients; seven had developed metastasis (8.1%) and all of them were in the Class 2 group, representing 21.2% of this group. Gene expression profile was an independent prognostic factor for relapse as indicated by multivariate Cox regression analysis, adjusted for AJCC stages and age. Conclusions: This prospective multicentre cohort study, performed in a Spanish Caucasian cohort, shows that this 31-gene expression profile test could correctly identify patients at early AJCC stages who are at greater risk of relapse. We believe that gene expression profile in combination with the AJCC staging system could well improve the detection of patients who need intensive surveillance and optimize follow-up strategies.

Subject

Melanoma, Anàlisi de regressió

Subject (English)

Melanoma, Regression analysis

Citation

Collections

Articles publicats en revistes (Medicina)

Citation

PODLIPNIK, Sebastian, et al. Early outcome of a 31-gene expression profile test in 86 AJCC stage IB-II melanoma patients. Journal of the European Academy of Dermatology and Venereology. 2019. Vol. 33, num. 5, pags. 857-862. ISSN 0926-9959. [consulted: 7 of August of 2026]. Available at: https://hdl.handle.net/2445/172407

Export metadata

JSON - METS

Share record